Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: The renal effects of nucleos(t)ide analogs in patients with chronic hepatitis B are controversial. We aimed to compare the impact of entecavir (ETV) and tenofovir (TDF) on renal function in patients with hepatitis B virus (HBV)-related cirrhosis. Methods: We performed a retrospective cohort study of 235 consecutive treatment-naïve patients with HBV-related cirrhosis who were treated with ETV or TDF between December 2012 and November 2013 at Severance Hospital, Seoul, Korea. Results: Compensated cirrhosis was noted in 183 patients (ETV 130, TDF 53), and decompensated cirrhosis was noted in 52 patients (ETV 32, TDF 20). There were no significant changes in estimated glomerular filtration rates (eGFR) from baseline in either the ETV- or TDF-treated groups at week 96 (Chronic Kidney Disease Epidemiology Collaboration, ETV –1.68% and TDF –5.03%, p=0.358). Using a multivariate analysis, the significant factors associated with a decrease in eGFR >20% were baseline eGFR, diabetes mellitus (DM), and the use of diuretics. The use of antiviral agents and baseline decompensation were not determined to be significant factors. Conclusions: In patients with HBV-related cirrhosis, TDF has shown similar renal safety to that of ETV over a 2-year period. Renal function should be closely monitored, especially in patients who exhibit decreasing eGFR, DM, and the use of diuretics.
Abstract
Background/Aims: The renal effects of nucleos(t)ide analogs in patients with chronic hepatitis B are controversial. We aimed to compare the impact of entecavir (ETV) and tenofovir (TDF) on renal function in patients with hepatitis B virus (HBV)-related cirrhosis. Methods: We performed a retrospective cohort study of 235 consecutive treatment-naïve patients with HBV-related cirrhosis who were treated with ETV or TDF between December 2012 and November 2013 at Severance Hospital, Seoul, Korea. Results: Compensated cirrhosis was noted in 183 patients (ETV 130, TDF 53), and decompensated cirrhosis was noted in 52 patients (ETV 32, TDF 20). There were no significant changes in estimated glomerular filtration rates (eGFR) from baseline in either the ETV- or TDF-treated groups at week 96 (Chronic Kidney Disease Epidemiology Collaboration, ETV –1.68% and TDF –5.03%, p=0.358). Using a multivariate analysis, the significant factors associated with a decrease in eGFR >20% were baseline eGFR, diabetes mellitus (DM), and the use of diuretics. The use of antiviral agents and baseline decompensation were not determined to be significant factors. Conclusions: In patients with HBV-related cirrhosis, TDF has shown similar renal safety to that of ETV over a 2-year period. Renal function should be closely monitored, especially in patients who exhibit decreasing eGFR, DM, and the use of diuretics.
참고문헌 (27)
- Ginès P, "Renal failure in cirrhosis", N Engl J Med, 361, pp.1279~1290 (2009)
- Moreau R, "Acute renal failure in patients with cirrhosis: perspectives in the age of MELD", Hepatology, 37, pp.233~243 (2003)
- Combes B, "Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane", Lancet, 2, pp.234~237 (1971)
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
- Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
- Ahn SH, "A 96-week randomized trial of switching to entecavir in patients who achieved virological suppression on lamivudine therapy", J Gastroenterol Hepatol, 31, pp.865~871 (2016)
- Fontana RJ, "Side effects of long-term oral antiviral therapy for hepatitis B", Hepatology, 49(5 Suppl), pp.S185~S195 (2009)
- Quesada PR, "Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients", Int J Clin Pharm, 37, pp.865~872 (2015)
- European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Gara N, "Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B", Aliment Pharmacol Ther, 35, pp.1317~1325 (2012)
- Liaw YF, "Tenofovir disoproxil fumarate (TDF), emtricitabine", TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, 2011, pp.53, 62~72
- Hwang HS, "Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection", Hepatology, 62, pp.1318~1320 (2015)
- 이상흔, "Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B", Gut and Liver, 9(6), pp.776~783 (2015), 거트앤리버 발행위원회
- Barrios A, "Tenofovir-related nephrotoxicity in HIV-infected patients", AIDS, 18, pp.960~963 (2004)
- James CW, "Tenofovir-related nephrotoxicity: case report and review of the literature", Pharmacotherapy, 24, pp.415~418 (2004)
- Jang JW, "Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis", Hepatology, 61, pp.1809~1820 (2015)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 22, pp.18~75 (2016)
- Matsushita K, "Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate", JAMA, 307, pp.1941~1951 (2012)
- Chang TT, "Long-term entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
- 안성수, "Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a singlecenter cohort", Clinical and Molecular Hepatology, 20(3), pp.261~266 (2014), 대한간학회[DOI]
- Najjar Z, "A survey of Sydney general practitioners’ management of patients with chronic hepatitis B", Med J Aust, 204, pp.74~ (2016)
- Chang TT, "Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B", Hepatology, 51, pp.422~430 (2010)
- Heathcote EJ, "Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B", Gastroenterology, 140, pp.132~143 (2011)
- Yip B, "Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders", Dig Dis Sci, 57, pp.3011~3016 (2012)
- Gish RG, "Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B", Clin Gastroenterol Hepatol, 10, pp.941~946 (2012)
- Ha NB, "Renal function in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or entecavir monotherapy: a matched case-cohort study", J Clin Gastroenterol, 49, pp.873~877 (2015)
- van Bömmel F, "Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside", nucleotide analogues, 2010, pp.51, 73~80